Effects of Levamisole in adjuvant immunochemotherapy for gastric cancer; a prospective randomized controlled study.
The effectiveness of Levamisole combined with Mitomycin-C, FT-207 and PS-K for treating gastric cancer was investigated in a prospective randomized controlled study. All patients had undergone gastrectomy during the years from August 1977 to November 1980. Five year survival rates revealed no difference between groups given or not given Levamisole. In those with positive lymph node metastases plus obvious serosal invasion, there was a significant elevation in the survival rate at four years after gastrectomy. The effectiveness of Levamisole was confirmed by postoperative changes in the PPD skin test, lymphocyte blastogenesis to PHA and serum inhibition index.
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007978:Levamisole / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009367:Neoplasm Staging; D011182:Postoperative Care; D011446:Prospective Studies; D011509:Proteoglycans / Q000008:administration & dosage; D011897:Random Allocation; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery
D000276:Adjuvants, Immunologic; D000903:Antibiotics, Antineoplastic; D008937:Mitomycins; D011509:Proteoglycans; D007978:Levamisole; C010770:polysaccharide-K; D016685:Mitomycin